米氮平治疗广泛性焦虑症的疗效及安全性  

Efficacy and safety of mirtazapine for the treatment of generalized anxiety disorder

作　　者：杨福收[1] 王新法[1] 王新友[1] 

机构地区：[1]新乡医学院第二附属医院精神药理教研室,新乡453002

出　　处：《中国新药杂志》2005年第5期619-621,共3页Chinese Journal of New Drugs

摘　　要：目的:探讨米氮平治疗广泛性焦虑症的疗效和不良反应。方法:对60例广泛性焦虑症患者随机分为试验组及对照组,分别服用米氮平15～30mg·d^(-1)和马普替林50～150mg·d^(-1),疗程均为6周。于治疗前及治疗后第1,2,4,6周末进行汉密尔顿焦虑量表(HAMD)及不良反应量表(TESS)评定疗效和不良反应。结果:试验组治疗广泛性焦虑症的显效率84.69%,有效率100%;对照组显效率66.67%,有效率88.89%,但两组比较经Ridit分析差异无显著性(P>0.05)。不良反应方面比较米氮平TESS评分显著低于马普替林(P<0.05)。结论:米氮平是治疗广泛性焦虑症的快速、安全、有效的药物。Objective: To evaluate the efficacy and safety of mirtazapine versus maprotiline in the treatment of generalized anxiety disorder (GAD). Methods: Of 60 patients with generalize anxiety disorder, 53 were randomly assigned to receive either mirtazapine (15～30mg·d^(-1), n=26) or maprotiline (50～150mg·d, n=27) for 6 weeks. The efficacy and safety of the study drugs were assessed with HAMD and TESS before the treatment and in weeks 1,2,4 and 6 after the treatment. Results: The overall response of mirtazapine and maprotiline was 84.69% and 66.67%, respectively, which showed no significant difference in Ridit analysis (P>0.05). The incidence of adverse events in the mirtazapine group was fewer than in the maprotiline group (P<0.05). Conclusion: Mirtazapine offers an alternative in the treatment of GAD.

关 键 词：米氮平 马普替林 广泛性焦虑症 

分 类 号：R947.7[医药卫生—药剂学] R969.4[医药卫生—药学]